# Developmental Research Program

> **NIH NIH P50** · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2022 · $124,768

## Abstract

Developmental Research Program (DRP): Project Summary / Abstract
The Developmental Research Program (DRP) will support the efforts of the Genetics and Genomics of
Leiomyosarcoma (LMS): Improved understanding of cancer biology and new approaches to diagnosis and
treatment SPORE. This DRP will complement or enhance the variety and depth of sarcoma translational
research, seeking to ensure continual renewal of high-quality translational scientific investigation. The DRP
supports short-range studies to establish the data needed to facilitate hypothesis-driven translational projects.
Although the DRP will fund established investigators, an important goal is to identify and stimulate interest in
sarcoma research among groups whose current focus may be different but sufficiently and transitionally related.
In addition, we seek to attract early and mid- career investigators and especially Black and Latino or Hispanic
investigators. Co-directing this program will be Steven Robinson, Associate Professor of Medicine at Mayo
School of Medicine. Dr. Robinson is a Jamaican born man educated in Jamaica. For the past 4 years he has
been supported by career development grants to Mayo Clinic including the institutional K12 as well as the Robert
Wood Johnson Foundation Amos Medical Faculty Development Program. Dr. Robinson is recent recipient of
Department of Defense IDEA Award. He also leads a ETCTN clinical trial that evaluates the combination of
TVEC with radiation therapy for localized sarcoma. Dr. Robinson will also participate in this SPORE by co-leading
our efforts to improve diversity in patients enrolled in clinical trials as well as increasing minority faculty
participation. Dr. Baker is the Co-Director of this DRP. He is the SPORE Principal Investigator. Dr. Baker has
made important contributions to the treatment of sarcomas beginning with the initial identification of doxorubicin
as an effective drug in sarcoma patients; the establishment of neo-adjuvant therapy strategy making
osteosarcoma and Ewing sarcoma curable diseases. Dr. Baker has an outstanding record of leadership and
collaboration within the sarcoma translational research field. Dr. Baker is most proud of his mentorship efforts.
Now 15 Professors of Medicine claim Dr Baker as their mentor.
Robinson and Baker are joined by a highly qualified committee of experienced clinician-scientists (DRP
Committee) which reviews and evaluates new pilot projects as the basis of providing recommendations to the
SPORE Executive Committee (Chair, Judy Garber) and the SPORE MPI, who bear the responsibility to select
DRP projects appropriate for funding. The DRP Committee includes members from major cancer centers who
possess expertise in key aspects of sarcoma science and therapeutics, including biology and genetics,
correlative science, sarcoma pathology, molecular diagnostics, sarcoma drug resistance, immuno-oncology and
statistical design and analysis. The DRP will provide the depth required to maintain inn...

## Key facts

- **NIH application ID:** 10493634
- **Project number:** 1P50CA272170-01
- **Recipient organization:** UNIVERSITY OF MICHIGAN AT ANN ARBOR
- **Principal Investigator:** LAURENCE HOWARD BAKER
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $124,768
- **Award type:** 1
- **Project period:** 2022-09-16 → 2027-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10493634

## Citation

> US National Institutes of Health, RePORTER application 10493634, Developmental Research Program (1P50CA272170-01). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10493634. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*